Dr. Sellers is a Core Institute Member and Director of the Cancer Program at the Broad Institute and a Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. He directs a research group focusing on the application of functional genomic technologies to the discovery of therapeutic vulnerabilities in cancer, and in parallel, finding new in roads to creating better and more effective therapeutics. Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at Novartis. Since joining Novartis in 2005 the oncology research group brought ~30 small molecule, biologic and cell-based cancer therapeutics into first-in-man trials. Ten therapeutics have reached market approval including encorafenib, alpelisib, ribociclib asciminib and tisagenlecleucel. During his tenure he conceptualized and directed the collaboration with the Broad Institute on the Cancer Cell Line Encyclopedia, the development of the Novartis Primary Derived Xenograft Encyclopedia and large-scale efforts to functionally characterize the cancer genome (Project DRIVE). Along with Dr. Carl June, he co-chaired the CART collaboration with the University of Pennsylvania that brought CTL019 to a recent FDA approval. He previously was an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute. Dr. Sellers received his B.S. from Georgetown University in 1982 and M.D. from the University of Massachusetts Medical School in 1986.